-
公开(公告)号：EP1217975A1
公开(公告)日：2002-07-03
申请号：EP00961691.3
申请日：2000-09-08
IPC分类号： A61F13/00
CPC分类号： A61K9/0014 , A61K9/7053 , A61K9/7061 , A61K47/186
摘要： A transdermal drug delivery system is disclosed, which includes a polymer, a drug and an amount of a quaternary ammonium salt that is sufficient to act as a penetration enhancer. The quaternary ammonium salt may also be present in an amount sufficient to act as an irritation reducer. Further, the transdermal drug delivery system may also contain a co-enhancer, which provides a synergistic skin permeation enhancing effect when combined with the quaternary ammonium salt. A method for enhancing the transdermal delivery of a drug is also disclosed.
-
2.发明授权TRANSDERMAL DRUG DELIVERY MATRIX FOR COADMINISTERING ESTRADIOL AND ANOTHER STEROID 失效透皮给药MATRIX雌二醇和另一种类固醇的同时交付
公开(公告)号：EP0921774B1
公开(公告)日：2006-09-13
申请号：EP97933279.8
申请日：1997-07-02
IPC分类号： A61F13/02 , A61K9/70 , A61K31/565
CPC分类号： A61K9/7061 , A61K31/565 , A61K2300/00
摘要： A matrix type transdermal patch for coadministering estradiol and another steroid wherein the matrix is composed of a N-vinyl-2-pyrrolidone-containing acrylic copolymer pressure sensitive adhesive, estradiol, the other steroid, and optionally a permeation enhancer, and the respective fluxes of estradiol and the other steroid from the matrix are independent of the respective concentrations of the other steroid and estradiol in the matrix.
-
公开(公告)号：EP1280486A1
公开(公告)日：2003-02-05
申请号：EP01927318.4
申请日：2001-04-24
IPC分类号： A61F13/00
CPC分类号： A61K9/0024 , A61K9/0014 , A61K9/0019 , A61K9/1647 , A61K9/7061 , A61K31/216 , A61K47/10 , A61K47/14 , A61K47/38 , A61K2300/00
摘要： The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.
-
公开(公告)号：EP1565136B1
公开(公告)日：2015-02-25
申请号：EP03781610.5
申请日：2003-10-31
IPC分类号： A61F13/00
CPC分类号： A61K9/7061 , A61F2013/00646 , A61K9/0014 , A61K9/0019 , A61K9/0024 , A61K9/1647 , A61K31/216 , A61K47/10 , A61K47/14 , A61K47/38 , A61K2300/00
-
公开(公告)号：EP1280486B1
公开(公告)日：2010-11-17
申请号：EP01927318.4
申请日：2001-04-24
IPC分类号： A61K31/216 , A61K9/70 , A61K47/10 , A61K47/14
CPC分类号： A61K9/0024 , A61K9/0014 , A61K9/0019 , A61K9/1647 , A61K9/7061 , A61K31/216 , A61K47/10 , A61K47/14 , A61K47/38 , A61K2300/00
摘要： The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.
-
公开(公告)号：EP0871420B1
公开(公告)日：2001-09-19
申请号：EP96911647.4
申请日：1996-04-08
CPC分类号： A61K9/7053 , A61K9/0014 , A61K9/7061 , A61K9/7069 , A61K47/14 , Y10S514/946
摘要： A composition and method for enhancing transdermal penetration of a basic drug are described. The composition comprises a matrix patch comprising an effective amount of a basic drug, preferably having a pKa of about 8.0 or greater, an effective amount of a penetration enhancer consisting essentially of triacetin, and a polymer layer preferably comprising a pressure-sensitive adhesive. A preferred basic drug is oxybutynin and acid addition salts thereof. The method for enhancing transdermal penetration comprises applying the matrix patch to a selected area of skin.
-
公开(公告)号：EP1565136A2
公开(公告)日：2005-08-24
申请号：EP03781610.5
申请日：2003-10-31
IPC分类号： A61F13/00
CPC分类号： A61K9/7061 , A61F2013/00646 , A61K9/0014 , A61K9/0019 , A61K9/0024 , A61K9/1647 , A61K31/216 , A61K47/10 , A61K47/14 , A61K47/38 , A61K2300/00
摘要： The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. In some aspects, the composition may be presented in the form of an unoccluded or free form topically administered gel.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.014 秒)
